Section Arrow
Quote
PGEN.NASDAQ
- Precigen
Quotes are at least 15-min delayed:2026/04/05 12:36 EDT
Regular Hours
Last
 3.94
+0.01 (+0.25%)
Day High 
4.03 
Prev. Close
3.93 
1-M High
4.275 
Volume 
5.46M 
Bid
3.92
Ask
4.01
Day Low
3.75 
Open
3.86 
1-M Low
3.04 
Market Cap 
1.39B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.47 
20-SMA 3.45 
50-SMA 4.03 
52-W High 5.465 
52-W Low 1.11 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.37/0.22
Enterprise Value
1.49B
Balance Sheet
Book Value Per Share
0.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.68M
Operating Revenue Per Share
0.06
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
COCPCocrystal Pharma1.51+0.49+48.04%-- 
BDRXBiodexa Pharmaceuticals plc0.8733+0.2593+42.23%-- 
IOBTIO Biotech0.0323-0.0114-26.09%-- 
GERNGeron Corp1.66------ 
ELABPmgc Holdings Inc5.72-8.28-59.14%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.